Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis
By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling. Wistar rats were randomized into eight groups: G1: non-osteoporotic; G2: osteoporotic; G3, G4, and G5: osteoporotic+SA (0.2, 0.4, and 0.8 mg/kg, respectively); G6, G7, and G8: osteoporotic+SA (0.2, 0.4, and 0.8 mg/kg, respectively)+simvastatin (0.4, 0.6, and 1 mg/kg, respectively). Osteoporosis was induced by dexamethasone (7 mg/kg, i.m.) once a week for 5 weeks. All treatments were administered for 8 weeks. Dexamethasone increased serum levels of alkaline phosphatase, calcium, phosphorus, and urea, especially in non-treated animals, which showed severe osteoporosis. Dexamethasone also induced bone microstructural fragility and reduced mechanical resistance, which were associated with a marked depletion in mineral mass, collagenous and non-collagenous protein levels in cortical and cancellous bone. Although SA has attenuated osteoporosis severity, the effectiveness of drug therapy was enhanced combining alendronate and simvastatin. The restoration in serum parameters, organic and inorganic bone mass, and mechanical behavior showed a dose-dependent effect that was potentially related to the complementary mechanisms by which each drug acts to induce bone anabolism, accelerating tissue repair..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Microscopy and microanalysis - 23(2017), 5, Seite 989 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Priscila L Sequetto [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1017/S1431927617012363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1998432424 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1998432424 | ||
| 003 | DE-627 | ||
| 005 | 20230715082052.0 | ||
| 007 | tu | ||
| 008 | 171125s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S1431927617012363 |2 doi | |
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1998432424 | ||
| 035 | |a (DE-599)GBVOLC1998432424 | ||
| 035 | |a (PRQ)p932-a61bee129b719d87b4fea1e7c966426f61f53bc1794ac1349371a82bf8a268480 | ||
| 035 | |a (KEY)0337614120170000023000500989lowdosesofsimvastatinpotentiatetheeffectofsodiumal | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q DNB |
| 100 | 0 | |a Priscila L Sequetto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a By using an experimental model of dexamethasone-induced osteoporosis we investigated the effects of different therapeutic schemes combining sodium alendronate (SA) and simvastatin on bone mineral and protein composition, microstructural and mechanical remodeling. Wistar rats were randomized into eight groups: G1: non-osteoporotic; G2: osteoporotic; G3, G4, and G5: osteoporotic+SA (0.2, 0.4, and 0.8 mg/kg, respectively); G6, G7, and G8: osteoporotic+SA (0.2, 0.4, and 0.8 mg/kg, respectively)+simvastatin (0.4, 0.6, and 1 mg/kg, respectively). Osteoporosis was induced by dexamethasone (7 mg/kg, i.m.) once a week for 5 weeks. All treatments were administered for 8 weeks. Dexamethasone increased serum levels of alkaline phosphatase, calcium, phosphorus, and urea, especially in non-treated animals, which showed severe osteoporosis. Dexamethasone also induced bone microstructural fragility and reduced mechanical resistance, which were associated with a marked depletion in mineral mass, collagenous and non-collagenous protein levels in cortical and cancellous bone. Although SA has attenuated osteoporosis severity, the effectiveness of drug therapy was enhanced combining alendronate and simvastatin. The restoration in serum parameters, organic and inorganic bone mass, and mechanical behavior showed a dose-dependent effect that was potentially related to the complementary mechanisms by which each drug acts to induce bone anabolism, accelerating tissue repair. | ||
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Calcium | |
| 650 | 4 | |a Bone (cancellous) | |
| 650 | 4 | |a Bisphosphonates | |
| 650 | 4 | |a Phosphorus | |
| 650 | 4 | |a Bone density | |
| 650 | 4 | |a Urea | |
| 650 | 4 | |a Collagen | |
| 650 | 4 | |a Restoration | |
| 650 | 4 | |a Rats | |
| 650 | 4 | |a Bone (cortical) | |
| 650 | 4 | |a Protein composition | |
| 650 | 4 | |a Bone resorption | |
| 650 | 4 | |a Bone mass | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Rodents | |
| 650 | 4 | |a Mechanical properties | |
| 650 | 4 | |a Fragility | |
| 650 | 4 | |a Biocompatibility | |
| 650 | 4 | |a Simvastatin | |
| 650 | 4 | |a Osteoporosis | |
| 650 | 4 | |a Sodium | |
| 650 | 4 | |a Bone | |
| 650 | 4 | |a Serum levels | |
| 650 | 4 | |a Biomedical materials | |
| 650 | 4 | |a Alkaline phosphatase | |
| 650 | 4 | |a Bone diseases | |
| 650 | 4 | |a Alendronic acid | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Bone composition | |
| 650 | 4 | |a Biology | |
| 700 | 0 | |a Reggiani V Gonçalves |4 oth | |
| 700 | 0 | |a Aloísio S Pinto |4 oth | |
| 700 | 0 | |a Maria G A Oliveira |4 oth | |
| 700 | 0 | |a Izabel R S C Maldonado |4 oth | |
| 700 | 0 | |a Tânia T Oliveira |4 oth | |
| 700 | 0 | |a Rômulo D Novaes |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Microscopy and microanalysis |d New York, NY : Cambridge University Press, 1997 |g 23(2017), 5, Seite 989 |w (DE-627)230486290 |w (DE-600)1385710-1 |w (DE-576)110772482 |x 1431-9276 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:5 |g pages:989 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1017/S1431927617012363 |3 Volltext |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1945044047 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_4012 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2017 |e 5 |h 989 | ||